UK doctors have developed a promising non-invasive test that could significantly change the way womb cancer is diagnosed in women experiencing postmenopausal bleeding. This new approach uses urine and vaginal fluid samples, potentially sparing thousands of women from invasive procedures like internal ultrasounds and hysteroscopies, which can be uncomfortable and costly for healthcare systems.
Currently, only a small percentage of women who report postmenopausal bleeding are diagnosed with cancer, yet the urgency of the situation often leads to invasive testing. The new test aims to identify those at higher risk for cancer while providing reassurance to the majority who do not have the disease. In a study involving nearly 1,900 women, the test accurately identified a significant number of cancer cases and returned negative results for most women without cancer.
While the test shows great promise, researchers caution that its accuracy may vary in different healthcare settings and that further studies are needed to confirm its effectiveness in routine practice. If validated, this test could transform the diagnostic pathway for womb cancer, reducing stress and unnecessary procedures for many women.
The implications of this development extend beyond individual health; it could lead to substantial cost savings for the NHS and improve overall patient care by streamlining the diagnostic process for womb cancer, a condition that affects many women worldwide.
Source: The Guardian
